ABSTRACT
ary damage as well as the primary damage is responsible for the injury occurring in the brain. The secondary damage is a situation depending on various physiopathological events and it could happen after hours or days from the primary brain damage. It has been proven that the secondary damage negatively influences the prognosis for the patients having TBI. Various mechanisms, such as neurotransmitter release, free radical formation, calcium dependent cell damage, gene activation, mitochondrial dysfunction, and inflammation, play role in the secondary damage. [1] Besides, activation of excitatory receptors, hypermetabolism, ischemia, lack of membrane ion pumps, increase in arachidonic acid metabolism, cerebral edema, and acute brain swelling can also mediate secondary damage. [2] The secondary brain injuries spread through neurochemical agents. [3] Excitatory amino acids, such as glutamate and aspartate increase after TBI. They cause swelling in cells, vacuolization, and neuronal death. They not only lead to entry of chlorine and sodium into cells and thus causing acute neuronal swelling but also lead to delayed cell destruction depending on entry of calcium into cells. 
INTRODUCTION
Head injury is one of the most commonly encountered problems in neurosurgery emergencies. Traumatic Brain Injury (TBI) occurring after head trauma continues to be a primary health problem despite all improvements in modern medicine. After trauma, primary brain injury occurs in central nerve system. Primary brain damage involves intracranial hemorrhage such as subdural hematoma, epidural hematoma, and intracerebral hematoma; skull fractures, scalp injury, brain contusion, and laceration. After head trauma, second-consumption along with inducement of serotonergic system and post-traumatic sympatho-adreno medullary axis further increase the damage. To summarize, various pathophysiological mechanisms are responsible for brain deterioration function, e.g., increased release of neurotransmitters, including acetylcholine, catecholamine, and glutamate occurring immediately after the stroke. [4] These are. Inflammation, which is responsible for the secondary damage, increases exitotoxity and intracranial pressure as a result of brain edema and unless effectively treated, it increases mortality and morbidity. For the treatment, commonly mannitol, hypertonic saline, hypothermia, barbiturate coma, and several anti-inflammatory drugs (TNF-alfa antagonists) are used. Some proinflammatory cytokines released after TBI cause microglial and astrocytic activation and this activation can increase the intensity of the damage. The leading proinflammatory cytokines are TNF-alpha, IL-1, and IL-6 which increase the severity of the damage by causing the secondary neuronal damage, destruction of the blood brain barrier, and cerebral edema. [5, 6] Etanercept is a dimer of a protein domain of recombinant TNF-alpha receptor that mediates its effect by binding to IgG1. As it is an antagonist of TNF-Alpha, it shows a strong anti-inflammatory effect. In the previous studies, it that use of etanercept in the patients withTBI has been shown to reduce the dysfunction of blood brain barrier, intracerebral infiltration of neutrophils, and death of neuronal cell. As a result of these, it leads to significant recovery. [7] Our aim in this study was to study the anti-edema, anti inflammatory and neuroprotective effects of etanercept in rats which underwent acute brain trauma.
MATERIALS AND METHODS
For this study, 40 male-adult Spraque-Dawley rats, weight ranging from 250g to 300g which have never participated in any test before, were used. The rats were procured from the Laboratory of Animal Studies and Production in Bolu Abant Izzet Baysal University. Until the experimental stage, they were fed with standard rat bait and tap water and kept in a cage for 12 hours night and 12 hours day time. During the whole experiment, standard conditions determined by the National Institute of Health in US were implemented. Induction of trauma and ongoing processes of the experiment were completed in the laboratory of Animal Studies and Production in Bolu Abant Izzet Baysal University. The ethical approval was obtained from the ethics committee of animal studies of Medical Faculty in Bolu Abant Izzet Baysal University on 13.02.2013 with 2012/62 code number.
Groups
Experiment animals were randomly divided into 4 groups, each of which has 10 rats.
Group 1 (Control group, C):
No head trauma was applied to the rats in this group and they were not given any treatment.
Group 2 (Trauma+NS group, TP):
Head trauma was applied to the rats in this group and then they were given NS.
Group 3 (Trauma+Dexamethasone group, TD): First, head trauma was induced in the rats in this group, then dexamethasone was given to them.
Group 4 (Trauma+Etanercept group, TE):
Head trauma was induced in the rats in this group and etanercept was given to them afterwards.
Anesthesia and Creating Trauma
Before Anesthesia, all test subjects were weighed and they were given 50 mg/kg ketamine hydrochloride by intraperitoneal route. After checking anesthetic depth by corneal reflex and tail pinch test, the physiological values such as breathing, pulse, rectal temperature of the animals were recorded at 0 th and 24 th hour (Table 1 , 2).
The animals were weltered in the groups in which trauma was to be induced. A skin incision was made along the mid-line in a way in which bregma and lambdoid suture could be seen. Periosteum was separated from the edges so that sutures could be seen totally from the front to the back. A steel disc with diameter of 10 mm and thickness of 3 mm (Figure 3a ve 4a) was placed into the midline between coronal and lambdoid sutures. Subsequently, the rats were placed in prone position on a sponge ground measuring 12x12x43 cm and the trauma tool was positioned as described by Marmarou. A 450g steel bar targeting the animal's head was dropped from 2 m height through a tube, with 19 mm inside diameter and 25 mm outside diameter. Rats whose respiration was stopped soon after the trauma and whose pupils were dilated and who had seizure (respiratory arrest, 5 rats; seizure, 3 rats) were resuscitated by performing CPR. The resuscitation was continued until the sufficient respiration recovered. The skin incisions were sutured with 2/0 silk suture. The animals whose respiration recovered were taken to their cages. Two rats killed during the trauma were replaced with the new ones, so the equal numbers in the groups were maintained. According to the treatment protocol in respective groups, the test subjects were given dexamethasone or etanercept via intraperitoneal route in various doses soon after the resuscitation. At 24 th hour, all animals were decapitated, their brain and brain stem were removed as a whole ( Fig. 1 ) and were fixed by 10% formalin.
Histopathologic Assessment
Brain materials, after fixation for 48 hours with 10% buffered formalin, were sliced in coronal plane, sampled as two from front to back and taken in tissue processing. Once they were dehydrated with the formalin, alcohol and xylene successively, paraffin blocks were prepared. After hydration and deparaf-finization, hematoxylin eosin stain and immunohisto-chemical stains such as anti caspase-3, anti İBA-1, anti GFAP, and anti NeuN were applied to 5 mm cross-sections taken from paraffin blocks, as the manufacturer states. The preparates studied by Nikon Eclipse 80i light microscope were transferred into the digital platform by Nikon DS-Fi1 camera attachment. In histopathological assessment, existence and severity of edema, and existence and severity of inflammation were used as variables. The existence of edema was assessed according to occurrence of microcystic areas by opening inside of the cells in parenchyma, however, the severity of edema was assessed as 1+ when edema is less than 10% in a magnification of 20x in microscope, 2+ when it is between 10% and 50% and 3+ when it is over %50. The existence of inflammation was conducted by searching the existence of leukocyte with polymorphic nuclei, lymphocyte, plasma cell and eosinophils.
Immunohistochemical Assessment
After the most affected sides in terms of cell damage were detected, preparates obtained as immunohistochemically were taken into the digital platform by taking view from the most effected sides three at a time during the large magnification (x200). The number of cytoplasmic cell GFAP, İBA, and Caspase 3 and the number of nuclear positive stained cell of NeuN was counted by means of digital program counter. In immunohistochemical assessment, astrocytes, microglial cells, severity and damage occurring in neurons, and severity and existence of glial apoptosis were taken as variables. The existence of glial apoptosis was conducted by searching, with anti Caspase 3, the existence of glial cell that shows cytoplasmic positivity. The damage occurring in astrocytes was detected by searching, with anti GFAP (Glial fibrillary acidic protein), the existence of cell that shows cytoplasmic positivity. The damage occurring in microglial cells was detected by searching, with anti Iba-1, existence of cell that shows cytoplasmic positivity while the damage occurring in neurons was detected by searching, with anti NeuN (Neuron-Specific Nuclear Protein), existence of cell that shows nuclear positivity. The severity of the occurring damage in cells was assessed as 1+ when the number of cells that shows nuclear and cytoplasmic positivity was less than 10%, 2+ when it was between 10% and 50%, and 3+ when it was over % 50.
Statistical Methods
For the statistical comparison, chi-square tests (q square test) and SPSS 15.0 were used and p value less than 0.05 was regarded as statically significant.
Findings
In the traumatic cases, in addition to edema and inflammation; microglial, astrocytic damage, and glial apoptosis were observed, however, in the dexamethasone group edema and inflammation decreased considerably and etanercept group all variables decreased significantly. The assessment of pathologies in different groups is shown in Table 3 . While edema, inflammation, microglial cell damage, neuronal damage, astrocytic cell damage, and glial apoptosis was detected in rats in the control group (Fig. 2) ; edema and inflammation were detected at level 1+ in 10 rats in the normal saline group, 2+ microglial cell damage in 8 animals, 2+ neuronal and astrocytic damage in 7 animals and 2+ glial apoptosis in 3 animals (Fig. 3) . In the dexamethasone group, edema and inflammation at 1+ level was observed in all rats except 5 animals, 2+ microglial cell damage in 7 rats, 2+ neuronal damage in 8 rats, 2+ astrocytic cell damage in 7 rats, and 2+ glial apoptosis in 4 rats (Fig. 4) .
In the etanercept group, edema and inflammation at 1+ level was observed in 1 rat while 9 rats didn't show any edema and inflammation. Other histopathological changes include 1+ microglial cell damage in 3 rats, 1+ neuronal damage in 1 rat, 1+ astrocytic cell damage in 3 rats, and 1+ glial apoptosis in 2 rats (Fig. 5) .
RESULTS
In our study, a statistically significant difference between the groups of trauma + dexamethasone and trauma + NS was observed according to the variables of edema and inflammation (p=0.027), but there was no significant difference according to the variables of neuronal damage, astrocytic damage, and glial apoptosis (p>0.05). A significant difference was observed between the groups of trauma + NS and trauma + etanercept in all variables (p=0.003). Lastly, a significant difference was observed between the groups of trauma + dexamethasone and trauma + etanercept in the variables of edema and inflammation (p=0.032), likewise, there was a significant difference in the variables of neuronal damage, astrocytic damage, and glial apoptosis (p=0.004).
DISCUSSION
TBI is one of the most commonly encountered traumas which occurs depending on head injury and is a pathological situation that can be fatal or crippling and usually requires a prolonged treatment and care. However, physiopathological mechanism of secondary brain injury appearing within minutes or even days following the primary brain injury due to the trauma is not clearly known. In recent years, studies have focused on some cellular and biochemical factors. The primary mechanisms causing the secondary injury include calcium dependent cell damage, neurotransmitter emission, free radical formation, gene activation, mitochondrial dysfunction, and inflammation. [1] Mortality and morbidity could be reduced with treatment by eliminating the factors causing secondary brain injury which significantly negatively affect the TBI prognosis. [8] In order to restrict the secondary biochemical damage and cell death in TBI, the effects of various pharmacological agents have been studied in various animal models. However, when these promising neuroprotective treatment protocols were applied to people, satisfactory success could not be obtained.
Some conceptual and methodological reasons increase the difficulties in transferring animal testing into clinics. [9] Among the reasons, first is that there is little similarity between the traumatic brain injury in human and induced brain trauma in animal models, second, insufficient drug distribution and shortage or inappropriate time in animal testing could be attributed. Besides, the fact that these studies target on only one mechanism is perhaps the most important reason. [10] In this study, etanercept treatment which is a TNF-alpha blocker in acute stage was given to the rats in which experimental head trauma was induced for studying the possible protective effects against the trauma-induced brain damage. On grounds of its similarity to diffuse head trauma seen in people and often occurring in motor vehicle crashes, a model of closed head injury in which the skull remains intact was practiced in this study as stated by Marmarou and Ark. [11] Tumor Necrosis Factor Alpha (TNFα) is called as cachectin and it is produced by many normal cells, tumor cells, and traumatic cells. It can also be produced by various stimulus such as viruses, bacteria, parasites, cytokines, and mitogens. In the solution, TNFα is a trimeric molecule which is both transmembrane and soluble. The secreted TNFα forms are biologically active. TNF-alfa is a cytokine the receptors of which have the capability to activate multiple signaling mechanisms due to their presence simultaneously in multiple locations and it has the capability to activate proinflammatory cytokines. In many studies conducted, it has been reported that TNFα plays an important role in TBI and leads to glial, microglial, astrocytic, and neuronal damage. [12] [13] [14] [15] [16] TBI is related with microglial and astrocytic cell activation, and the secretion of proinflammatory cytokines like TNFα and IL-1. [17] TNFα which is secreted after trauma and which is one of major proinflammatory cytokines of trauma plays an important role in inducing brain edema and neuronal cell damage, and in breaking down of blood brain barrier. Therefore, it is important to understand basic mechanism of TNFα levels and the consequences which increased after trauma. [6] It has been reported that TNFα causes extensive calcium build-up in cell and this triggers the process resulting in free radical formation and lipid peroxidation and at the same time it leads to calmodulin dependent nitric oxide synthase activity making up toxic hydroxyl radicals and hampering mitochondrial respiration. [16] Rising of intracellular calcium causes the break-down of oxidative phosphorylation, the formation of free radicals, the increasing of cellular enzymes, and death by dissolving of cell metabolism. [18] Etanercept is a recombinant TNFα antagonist which is effective when it binds TNF-alpha receptor proteins on lgG. Due to the antagonistic effect, it displays a strong anti inflammatory effect. It is preferred as a primary cure for many rheumatic diseases. The experimental studies in recent years have shown that etanercept could be beneficial in TBI. Etanercept cannot cross CSF due to its high molecular weight. However, The group given dexamethasone after trauma. It was observed that though edema and inflammation were seen, it was determined that there is no a specific change in microglial cell, neuronal, astrocytic cell damage and glial apoptosis. since blood brain barrier is broken down in TBI, it crosses CSF and it can display protective effect on glial cells, neurons, and microglial cells, and anti-inflammatory and anti-edema effect on cerebral tissue. [19] In some studies, it was reported that etanercept prevents leukocytes infiltration to protect brain and spinal cord from secondary damage, thereby inhibiting the inflammatory reaction of brain. [20, 21] In the research, it has been shown that in traumatic brain edema, vasogenic edema resulting from blood-brain barriers disruption is not the only reason of clinical deterioration, cellular edema associated with ischemia is also involved. [12] Increased secretion of proinflammatory cytokines like TNFalpha causes the imbalance of sodium and calcium, and this leads to ischemic edema. [22] [23] [24] [25] In a previous study on focal cerebral ischemia/reperfusion by Yoo-kyung Kim et al., central cerebral artery occlusion was done and after 24 hours reperfusion was enabled. Etanercept 5 mg/kg via intraperitoneal route was given 20 minutes before occlusion. Consequently, it has been proved that etanercept attenuates brain edema and infarct in all groups and it has neuroprotective effect. [16] In their study on neuroprotective effect of etanercept in spinal cord injury in rats, Ke-Bing Chen et al. exhibited with histopathological and biochemical parameters that etanercept has anti-inflammatory and anti-apoptotic effect, besides it has neuroprotective effect on neurons and oligodendroglias. They suggested that etanercept could be used as a neuroprotective agent in spinal cord injury. [17, 18] In our study, for edema and inflammatory variables, a statistically significant difference (p=0.027) between the groups of trauma+NS and trauma+dexamethasone was observed, whereas there was no significant difference (p>0.05) in terms of neuronal damage, astrocytic damage, and glial apoptosis variables. In terms of all variables, there was a significant difference (p=0.003) between the groups of trauma+NS and trauma+etanercept. On the other hand, the significant difference (p=0.032) was observed between the groups of trauma+dexamethasone and trauma+etanercept for edema and inflammatory variables and (p=0.004) for neuronal damage, astrocytic damage, and glial apoptosis variables. Edema and inflammation was seen in all 10 rats in trauma+NS group, in 5 rats in trauma+dexamethasone group and in only 1 rat in trauma+etanercept group; neuronal and astrocytic damage was seen in 7 rats in trauma+NS group; in trauma+dexamethasone group, neuronal damage was seen in 8 rats and astrocytic damage in 7 rats; in trauma+etanercept group, neuronal and astrocytic damage were seen in 2 rats. In addition, 2+ glial apoptosis in 3 rats in trauma+NS group, 2+ glial apoptosis in 4 rats in trauma+dexamethasone group and 1+ glial apoptosis in 2 rats in trauma+etanercept group were observed. This shows that both dexamethasone and etanercept have anti-inflammatory and anti-edema effect and anti inflammatory and anti-edema effects with latter showing stronger effects than former. It also shows that etanercept has neuroprotective effect.
Conclusion
Our study results have shown that etanercept has anti-inflammatory, anti-edema, and neuroprotective effects in acute traumatic brain injury and it can be protective against traumatic brain injury. We are of the opinion that for the treatment of traumatic brain injury, etanercept could be a beneficial option for people.
